Adlai Nortye Group Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
9.55
-0.73 (-7.10%)
At close: Oct 30, 2026, 4:00 PM EDT
9.81
+0.26 (2.72%)
After-hours: Oct 30, 2026, 7:31 PM EDT
Adlai Nortye Group Revenue
Adlai Nortye Group had revenue of $13.06M in the half year ending June 30, 2026. This brings the company's total for the last twelve months to $18.06M. In the year 2025, Adlai Nortye Group had annual revenue of $5.00M. That makes Adlai Nortye Group the 34,371st largest company in the world by revenue and 4,522nd in the United States.
Revenue (ttm)
$18.06M
Revenue Growth
n/a
P/S Ratio
34.06
Revenue / Employee
$165,651
Employees
109
Market Cap
615.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 45.73M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ANL News
- 3 days ago - Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium - GlobeNewsWire
- 16 days ago - Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab - TheFly
- 16 days ago - Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab - GlobeNewsWire
- 4 weeks ago - Adlai Nortye appoints Liu as Head of Investor Relations, Public Relations - TheFly
- 4 weeks ago - Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations - GlobeNewsWire
- 6 weeks ago - Adlai Nortye Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Adlai Nortye initiated with a Buy at Jefferies - TheFly
- 7 weeks ago - Adlai Nortye doses first patient in AN4035 trial - TheFly